John Tagliamonte
Directeur Général chez Mellitus LLC
Profil
John A.
Tagliamonte is currently the Chief Executive Officer & Director at Mellitus LLC.
Previously, he worked as the Director-Strategy & Business Development at Johnson & Johnson from 2001 to 2004, Manager-Global Product Lines at Bio-Rad Laboratories, Inc., Vice President-Business Development at ImmunoGen, Inc. from 2004 to 2005, Vice President-Business Development at Anchor Therapeutics, Inc., Chief Business Officer at HemoShear Therapeutics, Inc., Scientist-Cell & Molecular Biology at Dana-Farber Cancer Institute, Inc., Head-Business Development at Laureate Biopharmaceutical Services, Inc., Senior Vice President-Corporate Development at Selventa, Inc., and Chief Business Officer at Oxyrane UK Ltd.
He holds an MBA from Boston College and an undergraduate degree from Tufts University.
Postes actifs de John Tagliamonte
| Sociétés | Poste | Début |
|---|---|---|
Mellitus LLC
 Mellitus LLC BiotechnologyHealth Technology Mellitus LLC develops vitro diagnostic tests for the measurement of Glycated CD59 (GCD59). Its vitro diagnostic test is also used for the stratification of complications risk and as a clinical trial test for pharmaceutical development. The company was founded by Jose Alberto Halperin, Joyce A. Lonergan and Michael Chorev in 2011 and is headquartered in Boston, MA. | Directeur Général | - |
Anciens postes connus de John Tagliamonte
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | 01/01/2005 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Corporate Officer/Principal | - |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| BIO-RAD LABORATORIES, INC. | Corporate Officer/Principal | - |
Formation de John Tagliamonte
| Boston College | Masters Business Admin |
| Tufts University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| BIO-RAD LABORATORIES, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Selventa, Inc.
 Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Selventa, Inc. develops new approaches for the understanding and treatment of diseases. It focuses on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. The company was founded in 2002 by Keith O. Elliston and Noubar B. Afeyan and is headquartered in Cambridge, MA. | Commercial Services |
HemoShear Therapeutics, Inc.
 HemoShear Therapeutics, Inc. Medical/Nursing ServicesHealth Services HemoShear Therapeutics LLC engages in the development of human-relevant systems for applications in drug research and development. It creates human relevant systems that replicate the biology of organ systems and diseases throughout drug discovery and development. The firm's technology imposes human-derived hemodynamic forces on human primary cells to recreate human biology. The company was founded by Brian R. Wamhoff and Brett R. Blackman in 2008 and is headquartered in Charlottesville, VA. | Health Services |
Laureate Biopharmaceutical Services, Inc.
 Laureate Biopharmaceutical Services, Inc. Pharmaceuticals: MajorHealth Technology Laureate Biopharmaceutical Services, Inc. provides biopharmaceutical development and protein production services. It offers product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The firm's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply. The company was founded in 1981 and is headquartered in Princeton, NJ. | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Mellitus LLC
Mellitus LLC BiotechnologyHealth Technology Mellitus LLC develops vitro diagnostic tests for the measurement of Glycated CD59 (GCD59). Its vitro diagnostic test is also used for the stratification of complications risk and as a clinical trial test for pharmaceutical development. The company was founded by Jose Alberto Halperin, Joyce A. Lonergan and Michael Chorev in 2011 and is headquartered in Boston, MA. | Health Technology |
